Literature DB >> 25755493

Reversibility of hepatic fibrosis and cirrhosis-another evidence.

Ajay Duseja1.   

Abstract

Entities:  

Year:  2013        PMID： 25755493      PMCID： PMC4216436          DOI： 10.1016/j.jceh.2013.05.007

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN： 0973-6883


× No keyword cloud information.
  11 in total

1.  Reversibility of schistosomal periportal thickening/fibrosis after praziquantel therapy: a twenty-six month follow-up study in Ethiopia.

Authors:  Nega Berhe; Bjørn Myrvang; Svein G Gundersen
Journal:  Am J Trop Med Hyg       Date:  2008-02       Impact factor: 2.345

2.  Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases.

Authors:  Ludivine Falize; Anne Guillygomarc'h; Michele Perrin; Fabrice Lainé; Dominique Guyader; Pierre Brissot; Bruno Turlin; Yves Deugnier
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

3.  Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

Authors:  Ting-Tsung Chang; Yun-Fan Liaw; Shun-Sheng Wu; Eugene Schiff; Kwang-Hyub Han; Ching-Lung Lai; Rifaat Safadi; Samuel S Lee; Waldemar Halota; Zachary Goodman; Yun-Chan Chi; Hui Zhang; Robert Hindes; Uchenna Iloeje; Suzanne Beebe; Bruce Kreter
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

4.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Authors:  Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote
Journal:  Lancet       Date:  2012-12-10       Impact factor: 79.321

5.  Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B.

Authors:  Eugene R Schiff; Samuel S Lee; You-Chen Chao; Seung Kew Yoon; Fernando Bessone; Shun-Sheng Wu; Wieslaw Kryczka; Yoav Lurie; Adrian Gadano; George Kitis; Suzanne Beebe; Dong Xu; Hong Tang; Uchenna Iloeje
Journal:  Clin Gastroenterol Hepatol       Date:  2010-12-08       Impact factor: 11.382

6.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

Authors:  Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary Goodman; Jia Ma; Carol L Brosgart; Katyna Borroto-Esoda; Sarah Arterburn; Steven L Chuck
Journal:  Gastroenterology       Date:  2006-09-20       Impact factor: 22.682

7.  Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct.

Authors:  P Hammel; A Couvelard; D O'Toole; A Ratouis; A Sauvanet; J F Fléjou; C Degott; J Belghiti; P Bernades; D Valla; P Ruszniewski; P Lévy
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

8.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

Authors:  Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary Goodman; Michael S Wulfsohn; Shelly Xiong; John Fry; Carol L Brosgart
Journal:  N Engl J Med       Date:  2003-02-27       Impact factor: 91.245

9.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

10.  Histological outcome during long-term lamivudine therapy.

Authors:  Jules L Dienstag; Robert D Goldin; E Jenny Heathcote; H W L Hann; Mary Woessner; Sally L Stephenson; Stephen Gardner; D Fraser Gray; Eugene R Schiff
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682
View more
  1 in total

1.  Traditional Chinese medicine Yiqi Huoxue recipe attenuates hepatic fibrosis via YAP/TAZ signaling.

Authors:  Wen Zhao; Xiaoxiao Zhang; Mengmeng Hou; Yuguo Zhang; Yuhui Tang; Lu Li; Shiming Dong; Lingdi Liu; Dandan Zhao; Wencong Li; Yuemin Nan
Journal:  Histol Histopathol       Date:  2021-09-07       Impact factor: 2.303
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.